Abstract

New oral anticoagulants (NOACs) including dabigatran and rivaroxaban are approved for prevention of stroke in patients with atrial fibrillation (AF) [1]. To date, existing NOAC treatment is considered a contraindication for intravenous thrombolysis (IVT) in the case of acute stroke [2]. Nevertheless, rational approaches for the use of IVT in patients taking dabigatran have been published [3]. IVT under dabigatran treatment has been reported [4–6] but no data are available on rivaroxaban. Based on theoretical considerations, recent recommendations suggest that IVT might be considered in the case of low plasma levels of rivaroxaban [7]. We report on such cases. Case A

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.